(Reuters) – The U.S. Food and Drug Administration on Monday approved ScPharmaceuticals Inc’s therapy for patients with chronic heart failure.
The approval marks the end of a long path to the market for the therapy, Furoscix, after the regulator rejected it twice in the past.
The drug is delivered via an on-body infusor. Heart failure is a long-term condition in which the heart cannot pump enough blood to meet the body’s needs all the time.
(Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)
